More Change With Less Hoopla To FDA Out-Of-Specification Investigations Policy
Agency’s revised OOS guidance clarifies positions on outlier test results, averaging of HPLC results and some finer points around OOS questions. These could marginally improve compliance but won’t impact industry with nearly the force of the original 2006 guidance or the 1993 court ruling that preceded it.
You may also be interested in...
The Quality Lowdown: More Inspection Delays, More Findings On Sterility And Investigations
US FDA hits firms in New Jersey, South Korea and China with warning letters. Meanwhile, Catalent and several outsourcing facilities work on Form 483 inspection findings as Mylan, Viona and Lohxa announce drug recalls.
US FDA Warns Torrent Over Losartan Process Validation, OOS Invalidation Failures
Warning letter stemming from global nitrosamine investigation raises new concerns about Indian manufacturer.
The Next New Thing In FDA Inspections: Poor Root Cause Investigations
Data integrity failures are so yesterday. Now it’s all about poor investigations into out-of-specification results.